Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Weekly i.p. injections of killed Corynebacterium parvum and of cyclophosphamide (given on different days) strongly inhibited growth of a transplantable murine mammary adenocarcinoma. A significant portion (40 to 80%) of animals could be made tumor free by means of combined therapy. No tumor-free survivors were obtained with C. parvum alone, and tumor-free mice were obtained with cyclophosphamide alone only at the expense of a high incidence of deaths due to drug toxicity. No evidence of tumor rejection immunity was detected in the tumor-free survivors from the combined treatment protocols, suggesting that this therapeutic regimen is not associated with tumor rejection immunity.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000951:Antigens, Neoplasm; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection; D007167:Immunotherapy; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D011425:Propionibacterium acnes / Q000276:immunology*; D014185:Transplantation, Isogeneic
D000951:Antigens, Neoplasm; D003520:Cyclophosphamide